Novartis is responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.

Novartis response to COVID-19

In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to ...

Latest news


New peer-reviewed research shows no increased risk of serious COVID-19 infections in Kesimpta® (ofatumumab)-treated adults with multiple sclerosis

Read More


Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19

Read More


stopping this coronavirus and the next one

Stopping this coronavirus – and the next one

Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.


Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine

Oct 21, 2021

Read More

Enabling our associates to work safely on our sites

Oct 01, 2021

Read More

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

May 27, 2021

Read More

Molecular Partners’ COVID-19 antiviral candidate, Ensovibep, maintains potent neutralization against emerging viral variants in vitro

May 06, 2021

Read More



Novartis CEO joins Sal Khan in the Khan Academy Homeroom

In this podcast, Novartis CEO Vas Narasimhan and Sal Khan discuss about modern day breakthroughs in the world of medicine and what we can expect for the future of health as we emerge from COVID-19.

Listen to the Podcast

Novartis CEO outlines how to improve pandemic preparedness, warns another one is bound to happen

Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.


Test tubes

Can partnerships help boost vaccine supply?

An interview with Dr Steffen Lang, Global Head of Novartis Technical Operations on how Novartis is involved in manufacturing COVID-19 vaccines.

Latest stories

Novartis scientist on a blue background

Containing COVID-19 to serve patient needs

The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of ...


Nurse wearing a mask and gloves

Novartis COVID-19 Response Fund

Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.

Research and collaborations


Who Safe Greetings Illustration


World Health Organization (WHO)

WHO coronavirus disease (COVID-19) resources

Learn More

CDC's Tom Harkin Global Communications Center


US Centers for Disease Control and Prevention (CDC)

CDC coronavirus disease (COVID-19) resources

Learn More



International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

COVID-19 online hub

Learn More

Microsoft COVID-19 tracker


COVID-19 Tracker

Microsoft’s coronavirus disease outbreak tracker includes data from the WHO, CDC (US) and European CDC.

Latest Tracker